Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study
Open Access
- 18 July 2023
- journal article
- research article
- Published by Elsevier in JHEP Reports
- Vol. 5 (10) , 100851
Abstract
No abstract availableKeywords
Funding Information
- Innovative Health Initiative (821283)
- European Commission
- Horizon 2020 Framework Programme
- Innovative Medicines Initiative
- NIHR Nottingham Biomedical Research Centre (BRC-1215-20003)
- European Federation of Pharmaceutical Industries and Associations
This publication has 51 references indexed in Scilit:
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of MelanomaClinical Infectious Diseases, 2016
- RUCAM in Drug and Herb Induced Liver Injury: The UpdateInternational Journal of Molecular Sciences, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Case of Prednisolone-induced Hepatitis in a Patient with Ulcerative ColitisInflammatory Bowel Diseases, 2013
- Case Definition and Phenotype Standardization in Drug-Induced Liver InjuryClinical Pharmacology & Therapeutics, 2011
- A novel role of alkaline phosphatase in protection from immunological liver injury in miceLiver International, 2002
- Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.1987
- The Spectrum of HepatotoxicityPerspectives in Biology and Medicine, 1968
- Probable Inference, the Law of Succession, and Statistical InferenceJournal of the American Statistical Association, 1927